Budipine

Revision as of 13:41, 10 April 2015 by Turky Alkathery (talk | contribs)
Jump to navigation Jump to search
Budipine
File:Budipine.svg
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC21H27N
Molar mass293.446 g/mol
3D model (JSmol)
  (verify)

Budipine is an antiparkinson agent.

Its mechanism of action is not well characterized.[2] It is believed to be an NMDA receptor antagonist,[3] however, promoting the synthesis of dopamine.[4]

Because it provides additional benefits relative to existing treatments, it probably does not precisely mimic the mechanism of an existing known treatment.[5]

See also

References

  1. Martndale: The Complete Drug Reference, 35th Ed.
  2. Reichmann H (October 2006). "Budipine in Parkinson's tremor". J. Neurol. Sci. 248 (1–2): 53–5. doi:10.1016/j.jns.2006.05.039. PMID 16784759.
  3. J. Kornhuber, B. Herr, J. Thome, P. Riederer. "The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue". J.Neural Transm.Suppl. 46:127-133, 1995. PMID 8821048
  4. "umm.edu".
  5. Przuntek H, Bittkau S, Bliesath H; et al. (May 2002). "Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen". Arch. Neurol. 59 (5): 803–6. doi:10.1001/archneur.59.5.803. PMID 12020263.


Template:Antiparkinson


Template:Nervous-system-drug-stub